Kolexia
Raimbourg Judith Oncologie médicale
Raimbourg Judith
Oncologie médicale
Institut de cancérologie de l'Ouest
Saint-Herblain, France
112 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du poumon Carcinome pulmonaire à petites cellules Carcinome pulmonaire non à petites cellules Carcinomes Adénocarcinome Tumeurs colorectales Métastase tumorale Récidive tumorale locale Tumeurs de l'oesophage

Collaborateurs

Voir plus
Hiret Sandrine
Hiret Sandrine
Institut de cancérologie de l'Ouest, Saint-Herblain, France
Senellart Helene
Senellart Helene
Institut de cancérologie de l'Ouest, Saint-Herblain, France
Besse Benjamin
Besse Benjamin
Gustave-Roussy, Villejuif, France
Bennouna-Louridi Jaafar
Bennouna-Louridi Jaafar
Hôpital Foch, Suresnes, France

Industries

Voir plus
Pierre Fabre
7 collaboration(s)
Dernière en 2023
Takeda Pharmaceutical
6 collaboration(s)
Dernière en 2023
Amgen
4 collaboration(s)
Dernière en 2022
Servier
3 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
MOUNTAINEER-03: An Open-label Randomized Phase 3 Study of Tucatinib in Combination With Trastuzumab and mFOLFOX6 Versus mFOLFOX6 Given With or Without Either Cetuximab or Bevacizumab as First-line Treatment for Subjects With HER2+ Metastatic Colorectal Cancer
Essai Clinique (Seagen)   15 mars 2024
THROMBIN: Thrombin Generation and Prediction of Thromboembolic Events in Oncology Patients at Risk
Essai Clinique (Diagnostica Stago)   11 mars 2024
Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK): A Phase II Randomized, Open-Labelled, Multicenter Study of Safety & Efficacy of Combination Brigatinib and Carboplatin-Pemetrexed Therapy or Brigatinib Monotherapy as First-Line Treatment in Advanced ALK-Positive Non-Small Cell Lung Cancer
Essai Clinique (Intergroupe Francophone de Cancérologie Thoracique)   06 mars 2024
HERIZON-GEA-01: A Randomized, Multicenter, Phase 3 Study of Zanidatamab in Combination With Chemotherapy With or Without Tislelizumab in Subjects With HER2-positive Unresectable Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma (GEA)
Essai Clinique (Jazz Pharmaceuticals)   04 mars 2024
EORTC-SPECTA Arcagen study, comprehensive genomic profiling and treatment adaptation of rare thoracic cancers.
NPJ precision oncology   16 février 2024
Consore: A Powerful Federated Data Mining Tool Driving a French Research Network to Accelerate Cancer Research.
International journal of environmental research and public health   07 février 2024
Gemcitabine and Paclitaxel Versus Gemcitabine Alone After 5-Fluorouracil, Oxaliplatin, and Irinotecan in Metastatic Pancreatic Adenocarcinoma: A Randomized Phase III PRODIGE 65-UCGI 36-GEMPAX UNICANCER Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology   17 janvier 2024
A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer: A Randomized Phase 2 Study of Ompenaclid Versus Placebo in Combination With FOLFIRI Plus Bevacizumab in Patients With Previously Treated RAS Mutant Advanced or Metastatic Colorectal Cancer
Essai Clinique (Inspirna, Inc.)   17 janvier 2024
CheckMate 227: An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Subjects With Chemotherapy-Naïve Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Essai Clinique (BMS)   05 janvier 2024
Traitement des cancers bronchiques à petites cellules (CBPC) : intérêt des études en vie réelle. À propos de 2 études de l’IFCT : IFCT-1905 Clinatezo et IFCT-2105 Lurbiclin
28e Congrès de Pneumologie de Langue Française   01 janvier 2024